✦ LIBER ✦

Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial

✍ Scribed by Gerald G. Krueger; Boni Elewski; Kim Papp; Andrea Wang; Ralph Zitnik; Angelika Jahreis

Book ID: 116581409
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 277 KB
Volume: 54
Category: Article
ISSN: 1097-6787
DOI: 10.1016/j.jaad.2005.10.054

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical response to adalimumab treatmen

Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study

✍ Kenneth B. Gordon; Richard G. Langley; Craig Leonardi; Darryl Toth; M. Alan Ment 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 273 KB

Once weekly administration of etanercept

Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension

✍ P.C.M. Van De Kerkhof; S. Segaert; M. Lahfa; T.A. Luger; Z. Karolyi; A. Kaszuba; 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 372 KB

Assessment of antibodies to double-stran

Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α: Findings in open-label and randomized placebo-controlled trials

✍ P. J. Charles; R. J. T. Smeenk; J. De Jong; M. Feldmann; R. N. Maini 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 187 KB 👁 2 views

Objective. To compare the incidence of antidouble-stranded DNA (anti-dsDNA) antibodies in rheumatoid arthritis (RA) patients receiving either single or multiple doses of a chimeric anti-tumor necrosis factor ␣ (anti-TNF␣) antibody or placebo infusions, with or without methotrexate, in open-label, ra

Randomized, open-label, parallel-group e

Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: A noninferiority intensification substudy of the DURABLE trial

✍ William F. Miser; Richard Arakaki; Honghua Jiang; Jamie Scism-Bacon; Pamela W. A 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 873 KB

Marimastat may not improve survival over

Marimastat may not improve survival over placebo following induction therapy for small-cell lung cancer: Abstracted from: Shepherd F, Giaccone G, Seymour L et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002; 20(22): 4434–39.

✍ B Coudert 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 71 KB